Payment overview · 2025
General Payments
$784.01
40 reported records · 15 companies
Healthcare provider profile · identity verified
Amy North, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · QUINCY, IL · NPI 1699189332
Verified facts
What the public records show
CMS Open Payments records show Amy North, D.O. received $784.01 in general payments during 2025 across 40 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 14.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $113.28 | 14.4% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $105.26 | 13.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $102.77 | 13.1% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.48 | 9.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $64.16 | 8.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.44 | 8.1% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.44 | 7.7% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $50.56 | 6.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.84 | 5.0% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $28.03 | 3.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.17 | 2.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.05 | 2.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.49 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.86 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.18 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $784.01 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $105.26 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $102.77 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $84.00 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.44 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $60.44 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $50.56 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.60 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.03 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $28.03 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 113 | 92 |
| Gabapentin | Gabapentin | 105 | 28 |
| Furosemide | Furosemide | 86 | 23 |
| Alprazolam | Alprazolam | 80 | 13 |
| Pregabalin | Pregabalin | 69 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 62 | 17 |
| Losartan Potassium | Losartan Potassium | 57 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 23 |
| Tramadol Hcl | Tramadol Hcl | 52 | 26 |
| Sertraline Hcl | Sertraline Hcl | 49 | suppressed |
| Lisinopril | Lisinopril | 48 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 39 |
| Omeprazole | Omeprazole | 46 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 20 |
| Jardiance | Empagliflozin | 42 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 12 |
| Ozempic | Semaglutide | 41 | 11 |
| Potassium Chloride | Potassium Chloride | 41 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 38 | 14 |
| Atorvastatin Calcium | Atorvastatin Calcium | 38 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 19 |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 17 |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 15 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Cefdinir | Cefdinir | 21 | 17 |
| Nystatin | Nystatin | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Azithromycin | Azithromycin | 18 | 17 |
| Baclofen | Baclofen | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 11 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Dupixent Pen | Dupilumab | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Metformin Hcl | Metformin Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $784.01 · 40 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABILIFY ASIMTUFII, AIRSUPRA, CAPLYTA, COBENFY, Dexcom G6 Transmitter, FANAPT, JOURNAVX, KISUNLA, OFEV, OTEZLA, QULIPTA, REPATHA, REXULTI, TZIELD, UBRELVY, VRAYLAR, Veozah, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error